Details About Generic Salt ::  Diflunis

Main Medicine Class:: Analgesic,Salicylate   

(die-FLOO-nih-sal)

Dolobid,  Apo-Diflunisal, Novo-Diflunisal, Nu-Diflunisal

Class: Analgesic/Salicylate

 

Drugs Class ::

 Action Decreases inflammation and relieves pain by inhibiting prostaglandin synthesis and release.

Indications for Drugs ::

 Indications Relief of mild to moderate pain, rheumatoid arthritis and osteoarthritis.

Drug Dose ::

 Route/Dosage

Mild to Moderate Pain

ADULTS: PO 500 to 1000 mg for first dose, then 250 to 500 mg q 8 to 12 hr.

Arthritis

ADULTS: PO 250 to 500 mg bid. Maximum dose: PO 750 mg bid.

Contraindication ::

 Contraindications Hypersensitivity to NSAIDs or aspirin.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Not recommended for children < 12 yr. May increase risk of Reye’s syndrome; do not use if varicella infection or flu symptoms are suspected. Fluid retention: Use with caution in patients with CHF, hypertension or other conditions associated with fluid retention. History of peptic ulcer: Use carefully and closely monitor for GI bleeding or peptic ulcer; monitor patients with GI disease closely.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Peripheral edema. CNS: Headache; somnolence; insomnia; dizziness. DERM: Rash; erythema multiforme; photosensitivity. EENT: Angioedema; tinnitus. GI: Nausea; dyspepsia; GI pain; diarrhea; GI bleeding. GU: Renal impairment; interstitial nephritis; dysuria. HEMA: Thrombocytopenia; agranulocytosis; hemolytic anemia. HEPA Jaundice. RESP: Bronchospasm. OTHER: Anaphylaxis; hypersensitivity syndrome (eg, fever, chills, rash, liver or kidney dysfunction, leukopenia, thrombocytopenia, eosinophilia, DIC).

Drug Mode of Action ::  

 Action Decreases inflammation and relieves pain by inhibiting prostaglandin synthesis and release.

Drug Interactions ::

 Interactions

Antacids: Decreased plasma concentration of diflunisal. Cyclosporine: Increased nephrotoxic effect of cyclosporine possible. Methotrexate: Life-threatening methotrexate toxicity possible. Warfarin: Prothrombin time may increase; increased risk of bleeding.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess pain prior to and after administration of medication.
• Monitor I&O. Notify physician if signs of renal dysfunction occur (decreased urine output, elevated BUN, elevated creatinine).
• Include hepatic function in each assessment and notify physician if any signs or symptoms of hepatic dysfunction are noted (fatigue, jaundice, abdominal pain, elevated liver enzymes, dark urine).

OVERDOSAGE: SIGNS & SYMPTOMS   Drowsiness, vomiting, nausea, diarrhea, hyperventilation, tachycardia, sweating, tinnitus, disorientation, decreased urine output, cardiorespiratory arrest, stupor and coma; may lead to death.

Drug Storage/Management ::

 Administration/Storage

• Do not crush or allow patient to chew tablets.
• Administer with milk or food to minimize gastric irritation, give patient generous amounts of water or other fluids to increase gastric emptying.

Drug Notes ::

 Patient/Family Education

• Advise patient to swallow tablets whole and not to chew or crush them.
• Explain that relief of arthritis may not occur for 1 wk to several wks.
• Caution patients against taking products with aspirin or acetaminophen concurrently with diflunisal unless directed by physician.
• Warn patient that this medication can precipitate Reye’s syndrome.
• Advise patients to avoid exposure to sunlight and to use sunscreens or wear protective clothing to avoid photosensitivity reaction until tolerance is determined.
• Inform patients that first dose tends to have slower onset of pain relief than other drugs with comparable effects.
• Instruct patients to report immediately any signs of nephrotoxicity including decreased urine output, weight gain, edema, anorexia, nausea and vomiting.
• Advise patients with history of GI problems to notify physician if abdominal pain, melena or hematemesis develops during therapy.
• Advise patient to report degree of pain relief to physician.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.